# Lung Cancer ## Silymarin in Lung Cancer ### Overview Silymarin, a polyphenolic flavonoid complex extracted from milk thistle (*Silybum marianum*), has demonstrated significant anticancer activity in preclinical and clinical models of lung cancer. Research indicates its potential to inhibit tumour proliferation, induce apoptosis and necroptosis, modulate key signalling pathways such as MAPK, PI3K/AKT/mTOR, NF-κB, and STAT3/TIMP1, reduce metastasis (particularly brain metastases), enhance immunogenic cell death, and synergise with conventional therapies including EGFR tyrosine kinase inhibitors and immunotherapy.\ \ Studies investigate both standalone effects and interactions with chemotherapeutic and immunotherapeutic agents, positioning silymarin as a promising adjunctive agent worthy of further clinical investigation. ### How Silymarin May Work in Lung Cancer Silymarin exerts its effects through multiple interconnected mechanisms. Key pathways identified in laboratory and clinical studies include: * Inducing apoptosis via the mitochondrial caspase cascade pathway—increasing pro-apoptotic Bax, decreasing anti-apoptotic Bcl-2, and activating caspase-9, caspase-3, and PARP * Inducing necroptosis through upregulation and phosphorylation of necroptosis-related proteins (MLKL, RIPK1, RIPK3) and necrosome formation * Inhibiting the proliferation and invasion of non-small cell lung cancer (NSCLC) cells by inhibiting the activity of the MAPK pathway (specifically p-p38, p-JNK, p-ERK 1/2) * Suppressing matrix metalloproteinase (MMP) expression and activity (MMP-2, MMP-9), thereby reducing cancer cell invasion and metastasis * Inhibiting angiogenesis by reducing vascular endothelial growth factor (VEGF) expression and secretion * Modulating the tumour immune microenvironment by increasing phagocytic activity and decreasing CCL2 production * Exhibiting antioxidant and anti-inflammatory properties that may protect normal tissues while sensitising tumour cells to oxidative stress * Inhibiting the STAT3/TIMP1 signalling axis, which is associated with brain metastasis formation and resistance to anti-PD-1 therapy * Disrupting cell cycle progression through G0/G1 phase arrest via modulation of cyclin-dependent kinase activity * Enhancing Fas pathway activity by upregulating Fas and Fas ligand (FasL) expression, promoting death receptor-mediated apoptosis * Inhibiting PI3K activity, leading to a reduction of FoxM1 (Forkhead box M1) and subsequent activation of the mitochondrial apoptotic pathway ### Findings by Lung Cancer Subtypes and Models Silymarin and its major active component, silibinin, have demonstrated activity across various lung cancer cell lines, xenograft models, and clinical observations: ### Non-Small Cell Lung Cancer (NSCLC) Cell Lines * In A549 lung adenocarcinoma cells, silymarin treatment significantly inhibited proliferation in a dose-dependent manner, with notable effects at concentrations of 10 mg/L, 20 mg/L, and 40 mg/L * Silymarin increased the proportion of cells undergoing apoptosis and decreased mitochondrial membrane potential (MMP) in A549 cells * Treatment induced both apoptosis and necroptosis in A549 cells, with increased lactate dehydrogenase (LDH) release indicating necroptotic cell death * In the highly metastatic lung adenocarcinoma cell line Anip973, silymarin inhibited proliferation and induced apoptosis via the mitochondria-dependent caspase cascade pathway * Silymarin treatment reduced cell viability and increased apoptotic markers in H460 and H292 lung cancer cell lines * The compound inhibited cell migration and invasion in NSCLC models by suppressing MMP-2 and MMP-9 activity and downregulating EGFR, STAT5, and AKT phosphorylation ### Xenograft and Preclinical Models * In LLC-bearing mice, gastric administration of silibinin significantly inhibited tumour growth, with H\&E staining showing significant damage to tumour tissue * Immunohistochemical analysis revealed increased expression of RIPK1, RIPK3, and MLKL in tumour tissue from silibinin-treated mice, confirming necroptosis induction in vivo * Chronic oral consumption of silibinin (200 mg/kg, 5 days/week for 33 days) inhibited NSCLC A549 xenograft tumour growth and suppressed systemic toxicity of co-administered doxorubicin in athymic BALB/c nu/nu mice * Silibinin treatment impeded the regrowth of gefitinib-unresponsive xenograft NSCLC tumours, preventing tumour growth in vivo * The compound fully activated a reciprocal mesenchymal-to-epithelial transition in erlotinib-refractory cells and prevented the highly migratory phenotype of erlotinib-resistant NSCLC cells * Silibinin significantly lowered lung tumour multiplicity and prevented lung tumour development in chemically induced primary lung tumour models ### Brain Metastases and Clinical Observations * Silibinin has been shown to reduce brain metastases from lung cancer resistant to chemotherapy and radiation therapy * Oral supplementation with 420-1050 mg/day of Legasil™ (60% of silibinin isoforms) reduced brain metastases in patients with advanced lung cancer between 70% and 85% * Patients had previously received chemotherapy and radiation therapy without improvement, but demonstrated reduced brain metastases following silibinin supplementation * This represents the first reported effectiveness of silibinin in humans with cancer for reducing brain metastases * Silibinin appears to participate in maintaining quality of life for patients with brain metastasis, limiting worsening of neurological symptoms and improving perception of well-being * The compound overcomes secondary resistance to anti-PD-1 therapy in brain metastatic lung cancer patients by inhibiting the STAT3/TIMP1 signalling axis * Silibinin combined with EGFR-TKIs shows promise in NSCLC treatment, with studies evaluating its advantages and limitations ### Cancer Stem Cell Targeting While specific cancer stem cell (CSC) studies for silymarin in lung cancer are less extensive than in breast or colorectal cancer, mechanistic evidence supports potential effects: * Silymarin’s inhibition of epithelial-to-mesenchymal transition (EMT) through modulation of β-catenin, ZEB1, and related pathways may impact cancer stem cell properties * By suppressing the migratory and invasive capacity of lung cancer cells (via MMP inhibition), silymarin may target stem-like cells responsible for metastasis * The compound’s ability to induce both apoptosis and necroptosis may overcome resistance mechanisms in cancer stem cell populations * Silibinin’s epigenetic modulation of microRNAs (e.g., miR-21 oncogene and miR-200c tumour suppressor) may influence cancer stem cell-like phenotypes * In brain metastatic settings, silibinin’s effects on STAT3/TIMP1 signalling may target stem-like properties associated with treatment resistance and metastatic potential ### Chemosensitisation and Immunotherapy Synergy Silymarin demonstrates notable synergy with conventional and emerging lung cancer therapies: #### Chemotherapy * Silibinin suppresses systemic toxicity of co-administered doxorubicin through NF-κB regulation, allowing for potentially higher effective doses * The compound enhances the antitumor effects of standard chemotherapeutic agents while reducing adverse effects on normal tissues * Silymarin’s antioxidant properties may protect against chemotherapy-induced oxidative damage in healthy cells #### Immunotherapy * Silibinin overcomes secondary resistance to anti-PD-1 therapy in brain metastatic lung cancer patients by inhibiting the STAT3/TIMP1 signalling axis * The compound’s blood-brain barrier permeability allows it to reach central nervous system metastases, where it exerts anti-tumour effects * Combinations of grape seed procyanidin extract and milk thistle silymarin extract additively decrease lung cancer cell CCL2 production and increase phagocytic activity, enhancing antitumor immune responses * Silibinin may enhance the efficacy of PD-1 blockade by modulating the tumour immune microenvironment #### Targeted Therapy * Silibinin impedes regrowth of gefitinib-unresponsive xenograft NSCLC tumours, suggesting potential to overcome EGFR-TKI resistance * The compound fully activates mesenchymal-to-epithelial transition in erlotinib-refractory cells, countering resistance mechanisms * Studies are evaluating the potential of silibinin as a novel therapeutic agent for NSCLC when combined with EGFR-TKIs ### Radiotherapy Support Direct radiotherapy studies for silymarin in lung cancer are limited, but the mechanistic rationale supports investigation: * Silymarin’s antioxidant capacity may protect normal lung tissue from radiation-induced oxidative damage * By inhibiting NF-κB and reducing inflammatory cytokines, silymarin could mitigate radiotherapy-induced inflammation * Its anti-angiogenic and anti-metastatic effects may interfere with tumour repair and recurrence following radiation-induced damage * Silymarin’s immunomodulatory effects may enhance antitumor immune responses following radiation-induced antigen release * Preclinical models show silymarin reduces radiation-induced fibrosis and tissue damage via TGF-β/Smad pathway inhibition in other cancer types * Clinical trials evaluating silymarin during lung cancer radiotherapy are warranted, given its safety profile and mechanistic plausibility ### Practical Interpretation for Patients Silymarin is not a treatment for lung cancer, but research suggests it may offer many supportive benefits as an adjunct: * It may inhibit tumour proliferation and induce both apoptosis and necroptosis in lung cancer cells through mitochondrial and necroptotic pathways * It shows potential to reduce metastasis, particularly brain metastases, by inhibiting MMP activity and the STAT3/TIMP1 signalling axis * It appears to target cancer stem cell-like properties through EMT modulation and epigenetic regulation * It may enhance chemotherapy efficacy (particularly with doxorubicin) while reducing hepatotoxicity and other organ toxicities * It shows promise in overcoming resistance to EGFR tyrosine kinase inhibitors and anti-PD-1 immunotherapy * It has demonstrated favourable safety profiles in preclinical and clinical studies, with no significant liver or kidney toxicity observed at therapeutic doses * Any consideration should involve discussion with oncology professionals regarding timing (e.g., avoiding high-dose antioxidants during radiotherapy if pro-oxidant tumour effects are desired) and formulation (standardised extracts vs. nanoparticles) **Trusted product:** MCS Formulas Milk Thistle Silymarin 500mg\ 500 mg Milk Thistle extract per capsule, standardised to a minimum of 80% silymarin. Use the code `abbey5` at checkout to save 5% and help support the free Healing Cancer Study Support resources. ### References for Silymarin in Lung Cancer Exploring the anti-cancer and antimetastatic effect of Silymarin ... (2024): Silymarin: a promising modulator of apoptosis and survival signaling ... (2025): Silibinin is able to reduce brain metastases from lung cancer resistant to chemotherapy and radiation therapy - ESCOP (2018): Silymarin may inhibit the proliferation and invasion of non-small cell lung cancer cells by inhibiting the activity of MAPK pathway, and the higher the concentration, the more obvious the inhibition effect (2024): The STAT3/TIMP1 inhibitor silibinin overcomes secondary ... (2025): Combinations of Grape Seed Procyanidin Extract and Milk Thistle Silymarin Extract Additively Decrease Lung Cancer Cell CCL2 Production and Increase Phagocytic ... (2025): Silibinin Induces Both Apoptosis and Necroptosis with ... (2023): Molecular mechanism of silymarin-induced apoptosis in a ... (2011): Brain Metastatic Lung Cancer Patients: A Multitarget Therapeutic ... (2025): Lung Cancer Management with Silibinin: A Historical and ... - PMC (2021): Lung Cancer Management with Silibinin: A Historical and ... (2020): The STAT3/TIMP1 inhibitor silibinin overcomes secondary ... - PMC (2025): The Effects of Silibinin Combined With EGFR-TKIs in the Treatment ... (2025): Critical review of therapeutic potential of silymarin in cancer: {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/lung-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.